(Q51555289)

7 April 2018

title

Metabolic effects of fluoxetine in obese menopausal women. (English)

1 reference

7 April 2018

0 references

1 reference

M Bondi

1

1 reference

7 April 2018

R Menozzi

2

1 reference

7 April 2018

M Bertolini

3

1 reference

7 April 2018

M G Venneri

4

1 reference

7 April 2018

G Del Rio

5

1 reference

7 April 2018

publication date

1 May 2000

1 reference

7 April 2018

Journal of Endocrinological Investigation

published in

1 reference

7 April 2018

volume

23

1 reference

7 April 2018

issue

5

1 reference

7 April 2018

page(s)

280-286

1 reference

7 April 2018

https://scigraph.springernature.com/pub.10.1007/bf03343724

exact match

0 references

cites work

Norepinephrine, clonidine, and tricyclic antidepressants selectively stimulate carbohydrate ingestion through noradrenergic system of the paraventricular nucleus.

1 reference

https://api.crossref.org/works/10.1007%2FBF03343724

Fluoxetine in the treatment of obese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343724

Effect of gamma-irradiation on mouse pancreatic islet-allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343724

Overweight Prevalence and Trends for Children and Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343724

Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity

21 January 2018

1 reference

12 December 2020

Fluoxetine treatment of the obese diabetic

1 reference

12 December 2020

Fluoxetine-induced weight loss in overweight non-depressed humans

1 reference

12 December 2020

An assessment of the thermogenic effects of fluoxetine in obese subjects

1 reference

12 December 2020

Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub)

1 reference

12 December 2020

A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder

1 reference

12 December 2020

24-hour energy expenditure and the menstrual cycle

1 reference

12 December 2020

Fluoxetine's effect on weight loss in obese subjects

1 reference

12 December 2020

Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss

1 reference

12 December 2020

Fluoxetine increases resting energy expenditure and basal body temperature in humans

1 reference

12 December 2020

Overweight prevalence and trends for children and adolescents. The National Health and Nutrition Examination Surveys, 1963 to 1991

1 reference

12 December 2020

Fluoxetine kinetics and protein binding in normal and impaired renal function

1 reference

12 December 2020

The effect of fluoxetine on body weight, body composition and visceral fat accumulation

1 reference

12 December 2020

Neuropeptides, appetite regulation, and human obesity

1 reference

12 December 2020

A double-blind, placebo-controlled trial of the effect of fluoxetine on dietary intake in overweight women with and without binge-eating disorder

1 reference

12 December 2020

Serotoninergic modulation of the pattern of eating and the profile of hunger-satiety in humans

1 reference

12 December 2020

The pharmacologic profile of fluoxetine.

1 reference

12 December 2020

Reappraisal of the Weir equation for calculation of metabolic rate.

1 reference

12 December 2020

Determinants of decline in resting metabolic rate in aging females

1 reference

12 December 2020

Physical activity is a significant predictor of body density in women

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03343724

1 reference

7 April 2018

release_ehgvjhh2yfhspnuvi2m3t5gniq

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ehgvjhh2yfhspnuvi2m3t5gniq

24 November 2022

mapped directly with Wikidata item

1 reference

7 April 2018